Pulmonx Corp short interest falls 49% and schedules Q2 2026 earnings release

Pulmonx Corporation (NASDAQ:LUNG) reported a 49.2% decline in short interest during June, with short positions dropping to 1,148,892 shares, about 2.9% of the float and a short‑interest ratio of 1.3 days. Hedge funds increased their stakes: Bank of America lifted its holding by 60.3% to 1.17 million shares, ADAR1 Capital Management added 5.4%, and Renaissance Technologies grew its position by 9.7%. Institutional investors now own roughly 91% of the company.

The stock fell 3.4% to $1.43 in mid‑June trading. Pulmonx’s market capitalization stands at about $60.4 million, with a P/E ratio of –1.10, beta of 0.30, and a 12‑month price range of $1.13–$3.88. For the most recent quarter the company posted revenue of $20.59 million and a loss per share of $0.33.

Separately, Pulmonx announced it will release its second‑quarter 2026 financial results on July 29, 2026, via a live webcast.